T1	Participants 74 135	anthracycline-pretreated patients with advanced breast cancer
T2	Participants 347 376	international phase III trial
T3	Participants 676 738	day 1 (n = 255) or to docetaxel 100 mg/m(2) on day 1 (n = 256)
#1	AnnotatorNotes T3	2 groups
